How would you treat frontline metastatic ER+HER2- breast cancer with activating PI3K mutations?   

Outside of a clinical trial, I would still treat patients with HR+/HER2-, PIK3CA mutant, metastatic breast cancer with hormone therapy + CDK 4/6 inhibitor. At this moment, we are still awaiting approval of alpelisib. In the phase 3 SOLAR-1 trial, 341 patients with PIK3CA mutant tumors were randomize...